An empirical scheme to evaluate and prioritize screening hits from high-throughput screening (HTS) is proposed. Negative scores are given when chemotypes found in the HTS hits are present in annotated databases such as MDDR and WOMBAT or for testing positive in toxicity-related experiments reported in TOXNET. Positive scores were given for higher measured biological activities, for testing negative in toxicity-related literature, and for good overlap when profiled against drug-related properties. Particular emphasis is placed on estimating aqueous solubility to prioritize in vivo experiments. This empirical scheme is given as an illustration to assist the decision-making process in selecting chemotypes and individual compounds for further experimentation, when confronted with multiple hits from high-throughput experiments. The decision-making process is discussed for a set of G-protein coupled receptor antagonists and validated on a literature example for dihydrofolate reductase inhibition. (Journal of Biomolecular Screening 2005:419-426) 
INTRODUCTION

T
HE VIRTUAL AND HIGH-THROUGHPUT screening (HTS) worlds have often witnessed a large amount of interesting molecules (often in the order of 100-1000) that warrant further attention. 1 The answer to the question "What molecule(s) to pursue next?" is often left to the medicinal chemist 2, 3 or to the biologist 4 -who often have little else besides intuition to guide them in this analysis. We illustrate the decision-making process 5 based on a G-protein coupled receptor (GPCR) target, in which hits were evaluated via highthroughput flow cytometry. 6 In this particular workflow, we started with a 3-dimensional model of the GPCR (e.g., see Evers and Klebe 7 ) and docked (see Muegge and Enyedy 8 for review) known weak (micromolar) and strong (nanomolar) antagonists from the literature. Given the high level of uncertainty of this type of model, we derived a pharmacophore 9 and allowed large tolerance levels for the search, which we applied to the Chemical Diversity Labs (CDL) 10 library containing more than 450,000 compounds. The pharmacophore search produced 6500 compounds, of which a subset of 4324 compounds was available and screened. Based on the results from flow cytometry, 95 compounds (2.2%) were classified as HTS hits (i.e., some inhibition was observed), 76 compounds (1.8%) exhibited more than 50% inhibition, and 15 compounds (0.3%) were classified as antagonists, having K i values less than 10 µM on the GPCR target of interest. Because further in vitro and in vivo experiments are needed to improve the quality of these compounds for drug discovery, we discuss here the workflow for the decision-making process and the reasons for the empirical scoring scheme adopted here. This workflow is validated by applying the same empirical scheme on a set of 9 dihydrofolate reductase (DHFR) inhibitors, selected from 12 reported molecules. 11 These inhibitors were identified by screening a 50,000 small-molecule library via HTS then performing K i determination for 62 compounds in secondary screening.
GPCR antagonism, our evaluation scheme takes into account the total number of compounds screened per individual chemotype, expressed as the hits/tested (HT): "tested" represents the total number of compounds evaluated on this target in this flow cytometry screen, whereas "hits" were considered all compounds that exhibited at least 68% inhibition. The HT score evaluates the hit rate of a particular chemotype and captures negative information (e.g., inactives) as well. Individual biological activities are considered separately (see below). We applied the following criterion, according to the principle that a higher H/T ratio should be reflected by a higher HT score value: H/T ≥ 0.5, HT = 50; H/T ≥ 0.35, HT = 35; H/T ≥ 0.2, HT = 20; H/T ≥ 0.1, HT = 10; H/T ≥ 0.05, HT = 5; otherwise HT = 0. In the DHFR validation case, the chemotype evaluation was performed on 11 of the 12 reported molecules 11 using T = 20 (tested molecules) for each of the 5 chemotypes. We chose T = 20 as the default to minimize its influence on the rest of the analysis; the exact number of tested chemotype representatives was not reported. The H/T ratio scoring scheme for the DHFR example was the same as for the GPCR target. In this, and all other evaluation schemes presented in this work, scores are dimensionless. To distinguish between chemotypes, G and D are used to prefix GPCR antagonists and DHFR inhibitors, respectively.
Intellectual property evaluation scheme. We queried MDDR (MDL's drug data report 12 ) and WOMBAT (World of Molecular Bioactivity 13 ) for related substructures in an attempt to capture the value of various chemotypes with respect to drug discovery. We scored relevant chemotypes according to the principle that higher intellectual property (IP) scores should reflect a lower number of related substructures found in MDDR and WOMBAT. We awarded negative points for each hit in MDDR (-5 for identical and -1 for related [i.e., similar] substructures) and for hits in WOMBAT (we divided the total number of WOMBAT hits by -10). Higher weight was given to MDDR hits because it implies that the IP value of that substructure is already considered by a 3rd party for commercial applications, whereas WOMBAT hits are related more to public domain (not necessarily patents). In summary, we penalized each chemotype that had hits in any of these 2 databases.
Tox score and IPT score. We ran multiple queries in the TOXNET 14 database system for information available on substructures specifically related to the compounds in question. Choosing the appropriate fragments to query is more art than science (e.g., cyanide is highly toxic by itself but safe(r) in cimetidine), but every attempt was made to choose the relevant structural family. Thus, TOXNET queries did not always include the smallest substructure but rather fragments that were deemed relevant to bioactivity in that class. We applied the following criteria, according to the principle that higher Tox scores should be reflected by higher Tox values: negative toxicity studies for the exact substructure, Tox = 100; negative toxicity studies for related substructures, Tox = 50; known (potential) toxicity studies for related substructures, Tox = -50; known toxicity studies for the exact substructure, Tox = -100. In the absence of any other data, Tox = -10 (default), because all compounds are toxic (depending on the dose). Finally, we summed the HT, the IP, and Tox scores to evaluate the attractiveness of each chemotype in the IP and Tox (IPT) score.
Individual molecule evaluation
Physico-chemical property score. Because the next stage of experiments is in vivo mouse studies, the estimated permeability for each confirmed HTS active was evaluated at the individual level, given the chemotype context. Given the relatively high margin of error for solubility prediction methods, the solubility/permeability (SP) score was computed in rather large intervals, deemed to match the property distribution of orally available drugs, 15 17 For DHFR inhibitors, the corresponding values, precomputed with ACD/Labs software, 18 were extracted from SciFinder. 19 Minimum required aqueous solubility score. To prepare for experiments in mice, we applied the minimum required aqueous solubility test (min_S aq ) as follows:
where T w is the therapeutic window (typically 10 to 20 times higher than the K i ; in this study, T w = 20); K i is the measured inhibition constant, expressed in micromoles; and Vol is the total mouse blood volume (typically, and in this study, 5 mL).
where MW is the molecular weight (in atomic mass units) for each compound.
where S aq is the required solubility and SVol is the sample volume. In this study, SVol = 200 µL (this is the maximum fluid volume that can be given as bolus injection in mice).
The min_S aq test forces the estimated LogS aq (computed by either ChemoSoft 17 or ACD/Labs18) to exceed 10 times the required solubility dose (in equation 4, Log10). The required solubility (S aq ) is based on measured K i values and, as such, reflects a "must-have" for the success of the in vivo experiments. The 10-times excess value reflects the possible errors in computing LogS aq . The min_S aq test was applied to all compounds with available estimated LogS aq and measured K i values. Fifty points were awarded to compounds passing this test, and 50 points were subtracted from the score of compounds that failed this test.
High activity and priority scores. To take into account biological potency, we scored compounds according to their measured activity on the target of interest, as follows: For the GPCR antagonists, 100 points were awarded for 10 µM ≥ K i ≥ 1 µM; 50 points were awarded for K i between 10 and 20 µM, 20 points for K i between 20 and 40 µM, and 10 points for K i that had higher values. For the DHFR inhibitors, compounds were scored according to the K i as follows: 80 points were awarded for 5 nM > K i ≥ 1 nM, 60 points were awarded for 10 nM > K i ≥ 5 nM, 40 points were awarded for 50 nM > K i ≥ 10 nM, 20 points for 0.1 µM > K i ≥ 50 nM K i , 10 points for 0.5 µM > K i ≥ 0.1 µM, and 1 point for K i above 1 µM. The score variation between the 2 targets reflects the limited distribution of the bioactivities for the DHFR inhibitors (only 9 structures scored) compared to the GPCR antagonists (33 structures ranked). The priority score was computed by summing the IPT (chemotype) score, the SP, and the min_S aq scores, as well as the K i score.
RESULTS AND DISCUSSION
Chemotype evaluation results for the GPCR set
HT scores and bioactivities recorded for each chemotype in the MDDR and WOMBAT databases are presented in Figure 1 . All chemical substructures depicted in Figure 1 follow the following (ISIS/base) convention: Dashed lines represent any bond type, A searches for "any atom except hydrogen," and hydrogens are not explicit (unless specified). The HT evaluation scheme produces some interesting contrasts: 3 chemotypes (G.A, G.B, and G.E) are awarded the highest score, 50, whereas dihydropyridines and flavones (G.C and G.H) are awarded very low scores. The HT score, although not related to the potency of individual compounds, incorporates information about HTS negatives; these are usually ignored in structure-activity studies. Thus, low scores in families G.C and G.H reflect the fact that a relatively large number of analogs were found to be inactive on this GPCR target, compared to, for example, rhodanines (G.E), in which 3 out of 3 compounds are active. Figure 1 highlights in bold the instances in which bioactivity information related to GPCR targets was recorded for this chemotype. Three out of 9 families have GPCR-related activities: The dihydropyridines (G.C) exhibit, besides calcium channelblocking activity, antagonism on NPY, PAF, alpha adrenergic, and adenosine receptors. Chemotype G.D (in particular, 2,3-pyrrolidinediones) are CCR2 antagonists, besides exhibiting aldose reductase inhibition activity, whereas chemotype G.H (flavones) are dopamine-2 and sigma receptor antagonists, as well as kinase inhibitors. Figure 1 also underscores the potential promiscuity of some families (e.g., coumarins, G.G) that hit a variety of unrelated targets (including dopamine D4 receptors), whereas some other families (e.g., G.A) are much less explored according to patents and medicinal chemistry literature. Low scores in the IP arena (e.g., for dihydropyridines and coumarins, see Fig. 1 ) made these particular chemotypes less appealing: It is quite likely that compounds of interest are already being investigated or patented for some related activity. Further optimization in this chemical space is therefore considered a more difficult task.
We did not limit ourselves to evaluating the IP potential of these chemotypes but proceeded to evaluate available toxicity information. Families G.B (pirazolo-pyridines) and G.G (coumarins) were penalized because of known contraceptive (G.B) and carcinogenic (G.G) activities, whereas families G.E (rhodanines) and G.H (flavones) were awarded high scores for being found relatively nontoxic. Given the composite IPT score, 3 chemotypes were highlighted for further investigation: rhodanines (G.E), flavones (G.H), and pyrrolidinediones (G.D).
Individual molecule evaluation results for the GPCR set
Individual molecules were evaluated in the context of chemotype scores, to which we added information related to the estimated physico-chemical properties (solubility/permeability), the minimum required aqueous solubility test (min_S aq ), and the measured biological activity, to derive the final priority score. The results for the top 12 ranked molecules are presented in Figure 2 . Because solubility and high activity were given high scores when planning the mice experiments, it is not surprising that the rhodanine (G.E) chemotypes with K i values of 4 and 6 µM are the top 2 molecules. It is reassuring to note that rhodanine itself is not carcinogenic and that rhodanine derivatives have not been heavily investigated in the GPCR arena (see Fig. 1 ).
Four other top-ranked molecules are from the G.A (cyclohexanedione) chemotype-with K i values between 1 and 21 µM-and 1 of them passes the min_S aq test (Fig. 2) . With as little as is known about the potential bioactivity and toxicity of these compounds, they are not considered the highest priority. The 3rd-ranked priority chemotype, pyrrolidinediones (G.D), is penalized due to its low solubility, even though the chemotype itself was considered quite interesting and even though the compound has promising activity (4 µM). Flavones (G.H) represent the 4th chemotype in the priority score, with K i values between 2 and 10 µM; 1 of them, with K i = 6 µM, almost passed the min_S aq test. This chemical family has a rather high number of tested analogs (182), of which only 11 show any activity (see Fig. 1 ). It was, therefore, difficult to assign them a high priority, even though related compounds pass the carcinogenicity tests.
Chemotype and individual molecule analyses for the DHFR inhibitors set
The utility of the post-HTS prioritization scheme was further tested on a set of DHFR inhibitors, recently identified via HTS and confirmed by secondary screening. 11 The chemotype prioritization scheme, including HT scores, recorded bioactivities for each chemotype from MDDR and WOMBAT, as well as the TOXNET and IPT score (Fig. 3) . Figure 4 , once the measured biological activity, the estimated physico-chemical properties (SP), and the minimum required aqueous solubility test (min_S aq ) are included in the final score. Trimethoprim (the 6th molecule in Fig. 4) is given a middle-tier priority, illustrating how good activity and physico-chemical properties can offset even the lowest IPT score for this group. Our post-HTS evaluation scheme is validated by the fact that all top 5 molecules ranked in Figure 4 are previously unreported DHFR inhibitors (in the context of the initial publication D.E, D.B, and D.D chemotypes) , further illustrates the advantage of using such prioritization schemes, compared to simple bioactivity ranking. In contrast, if one were to use only K i values to rank the same 9 molecules discussed in Figure 4 , the top candidate would be trimethoprim (D.C), followed by the benzyl-amidino- The most interesting molecule according to our own analysis, the phenyl-biguanide (D.E), would rank 5th, whereas the 5,6,7,8-tetrahydroquinazoline-2,4-diamines (D.B) chemotype would be at the bottom of the activity-ranked list. Albeit empirical, we believe this scheme is supported by the DHFR inhibitors analysis, further highlighting the need for more complex decision-making schemes when selecting candidates for additional investigation.
CONCLUSIONS
This article illustrates practical steps related to the evaluation of compounds for further experiments, once the HTS actives have been analyzed and confirmed and once their dose-response curves have been determined. The HT score captures information related not only to actives but also to inactives from the same chemical family, whereas the IP evaluation scheme and the Tox score are aimed at encoding information related to individual chemotypes, as they are available in various sources. At the individual molecule level, an example of how estimated physico-chemical properties can be included in the final prioritization score is given, starting with the property profile of known drugs. 15 For practical reasons, the minimum required aqueous solubility score is given a high weight, equal to the score awarded for high biological activity. Given enough resources, we encourage the use of measured physico-chemical properties such as LogS aq and LogD 74 instead of computed ones to serve better the decision-making process.
Whenever the situation demands it, for example, a rather large number of distinct chemical families have emerged from primary and secondary HTS assays, the user can automatically derive Tox scores via expert systems, for example, using DEREK 20 and MULTICASE. 21 The output of these methods, when given in numeric form, can be directly used in the IPT score. An alternative is to sort the HTS hits according to chemotype and bioactivity values, then evaluate the top X structures (where X is 3, 5, etc.) from each chemotype by querying appropriate literature or rule-based systems, then incorporating these results at the compound (rather than chemotype) level. It is not surprising that the top 3 ranking GPCR chemotypes are among the top 4 recovered in the final priority score, but it is reassuring to note that, among these 3 chemotypes, rhodanine has high solubility, whereas the other 2 include analogs known to be active on GPCR targets. The fact that 2 DHFR inhibitors from previously unreported chemotypes are prioritized in the top 4 candidate molecules further validates this empirical scheme. We note that with the exception of a minor change related to biological activity scoring, the same empirical scoring scheme was applied in both the GPCR and DHFR data sets.
This article, aimed at showing how post-HTS analyses can be done, offers a practical method to encode information that is deemed relevant to preclinical drug discovery scientists and to doc- ument the decision-making process 5 in the lead identification stage. By changing the weighting schemes to tailor particular projects or laboratories, one can monitor and understand the various factors that need to be considered in compound prioritization. For example, companies that have excellent IP portfolios in the dihydropiridine or 2,4-diamino-pyrimidine arenas might give these chemotypes (G.C and D.E, respectively) a much higher priority because it is less likely that G.C compounds will cause cardiac toxicity and because their toxicity profile is already well understood. 
